N-Acetyl Semax and N-Acetyl Selank

What Are N-Acetyl Semax and N-Acetyl Selank?

Semax and Selank are two separately developed Russian peptides with real, decades-long research and clinical use histories. Semax is derived from a fragment of ACTH and has been studied primarily for stroke recovery and neuroprotection. Selank is derived from tuftsin and has been studied primarily for anxiety-related effects. Both are approved as prescription medications in Russia.

N-Acetyl Semax and N-Acetyl Selank add an acetyl group to the front of each peptide's structure. This modification is commonly marketed as improving how well the peptide is absorbed through the nasal lining and how resistant it is to breakdown, based on general principles of peptide chemistry. It's important to be direct about the evidence here: the published clinical and mechanistic research on Semax and Selank was conducted using the original, unmodified peptides. No dedicated published studies specifically testing the acetylated variants were identified, so any absorption or stability claims for these versions are extrapolated from general chemistry rather than demonstrated directly.

What This Research Is Actually Based On

• Semax's Original Research Base

  The clinical evidence behind Semax comes from Russian trials in acute ischemic stroke, where it was studied alongside standard treatment and tracked using clinical and electrophysiological measures.^[1]

• Semax and Neurotrophic Signaling

  Separate mechanistic research found Semax increases levels of brain-derived neurotrophic factor (BDNF) in animal models, providing a proposed biological basis for its neuroprotective research.^[2]

• Selank's Original Research Base

  The clinical evidence behind Selank comes from Russian trials comparing it to a standard anxiolytic medication in patients with generalized anxiety disorder and neurasthenia.^[3]

How the Underlying Peptides Work

• Semax and BDNF

  Research points to Semax increasing brain-derived neurotrophic factor levels in relevant brain regions without triggering the cortisol-releasing activity of full-length ACTH, which is the proposed basis for its neuroprotective research.^[2]

• Selank and Enkephalin Preservation

  Research points to Selank slowing the breakdown of the body's own enkephalin signaling molecules, alongside effects on GABA and other neurotransmitter systems, which is the proposed basis for its anxiolytic research.

• What the Acetyl Modification Changes

  The acetyl group is a common chemical strategy used across peptide chemistry generally to reduce enzymatic breakdown and potentially improve mucosal absorption. Whether it meaningfully changes Semax or Selank's specific activity, rather than just their stability in storage or transit, has not been directly tested in published research.

Reconstitution and Handling

Both variants are typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting, though both original compounds are also commonly studied and used in intranasal form. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

N-Acetyl Semax and N-Acetyl Selank are marketed modifications of two peptides with genuine research and clinical histories, but the modification itself hasn't been directly studied. Anyone researching these compounds should treat the underlying Semax and Selank literature as the real evidence base, and treat absorption or potency claims specific to the acetylated versions as unverified extrapolation rather than demonstrated fact.

Frequently Asked Questions

Sources and Research

1. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34.
2. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin(4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86.
3. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.